MCID: PRT096
MIFTS: 50

Peritoneal Mesothelioma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Peritoneal Mesothelioma

MalaCards integrated aliases for Peritoneal Mesothelioma:

Name: Peritoneal Mesothelioma 12 14 69
Malignant Mesothelioma of Peritoneum 12 69
Advanced Malignant Mesothelioma of Peritoneum 12
Advanced Malignant Peritoneal Mesothelioma 12
Advanced Peritoneal Malignant Mesothelioma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1788
ICD10 33 C45.1
NCIt 47 C8704 C9350
SNOMED-CT 64 109853004 187806007

Summaries for Peritoneal Mesothelioma

Disease Ontology : 12 A peritoneum cancer that develops from cells of the mesothelium and is located in the peritoneum.

MalaCards based summary : Peritoneal Mesothelioma, also known as malignant mesothelioma of peritoneum, is related to ocular melanoma and seminoma, and has symptoms including abdominal pain An important gene associated with Peritoneal Mesothelioma is THBD (Thrombomodulin), and among its related pathways/superpathways are Pathways in cancer and Endometrial cancer. The drugs Doxorubicin and Doxil have been mentioned in the context of this disorder. Affiliated tissues include lung, colon and pancreas, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 72 Peritoneal mesothelioma is the name given to the cancer that attacks the lining of the abdomen. This... more...

Related Diseases for Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 210)
id Related Disease Score Top Affiliating Genes
1 ocular melanoma 29.7 CDKN2A EGFR MUC1
2 seminoma 29.1 NF2 WT1
3 benign multicystic peritoneal mesothelioma 12.4
4 malignant peritoneal mesothelioma 12.3
5 benign peritoneal mesothelioma 12.2
6 peritoneal cystic mesothelioma 11.0
7 peritonitis 10.9
8 luminal breast carcinoma 10.7 EGFR MUC1
9 malignant giant cell tumor of soft parts 10.7 CDKN2A EGFR
10 spindle epithelial tumor with thymus-like differentiation tumor 10.6 CDKN2A EGFR
11 pulmonary type ovarian small cell carcinoma 10.6 CDKN2A MUC1
12 diffuse meningeal melanocytosis 10.6 CDKN2A MUC1
13 gallbladder pleomorphic giant cell adenocarcinoma 10.6 MUC1 NF2
14 spindle cell liposarcoma 10.6 CDKN2A MUC1
15 noninvasive malignant thymoma 10.6 MUC1 NF2
16 neurofibroma of the esophagus 10.6 CDKN2A MUC1
17 plummer vinson syndrome 10.6 CDKN2A MUC1
18 rete testis neoplasm 10.6 CDKN2A EGFR
19 pleural empyema 10.6 MUC1 NF2
20 gastric tubular adenocarcinoma 10.6 EGFR ESR1
21 anaplastic oligodendroglioma 10.6 MUC1 NF2
22 cervical adenosquamous carcinoma 10.6 CDKN2A NF2
23 multiple carboxylase deficiency 10.6 CDKN2A EGFR
24 benign pleural mesothelioma 10.6 CDKN2A NF2
25 gastroesophageal junction adenocarcinoma 10.6 ESR1 MUC1
26 phobic disorder 10.6 CDKN2A MUC1
27 kidney clear cell sarcoma 10.5 EGFR ESR1
28 vulvar squamous papilloma 10.5 ESR1 MUC1
29 dmd-related dilated cardiomyopathy 10.5 EGFR ESR1
30 superficial basal cell carcinoma 10.5 CDKN2A ESR1
31 sarcomatoid squamous cell skin carcinoma 10.5 CDKN2A ESR1
32 breast myoepitheliosis 10.5 CDKN2A ESR1
33 lethal restrictive dermopathy, zmpste24-related 10.5 EGFR VEGFA
34 advanced sleep phase syndrome 10.5 CDKN2A MUC1
35 exotropia 10.5 MUC1 WT1
36 middle ear squamous cell carcinoma 10.5 CDKN2A EGFR
37 breast sarcoma 10.5 ESR1 MUC1
38 malignant thyroid stimulating hormone producing neoplasm of pituitary gland 10.5 EGFR ESR1
39 malignant peritoneal solitary fibrous tumor 10.5 THBD WT1
40 pulmonary artery choriocarcinoma 10.5 CDKN2A WT1
41 epithelioid sarcoma 10.5 MUC1 WT1
42 epidural neoplasm 10.5 CDKN2A VEGFA
43 fibrous meningioma 10.5 CDKN2A WT1
44 ovary papillary carcinoma 10.5 MUC1 WT1
45 ovary neuroendocrine neoplasm 10.5 MUC1 WT1
46 comedo carcinoma 10.5 EGFR ESR1
47 coronary restenosis 10.4 MUC1 VEGFA
48 pancreatic ductal carcinoma 10.4 MUC1 WT1
49 sparse hair ptosis mental retardation 10.4 EGFR VEGFA
50 sphenoid sinus squamous cell carcinoma 10.4 KRT20 THBD

Graphical network of the top 20 diseases related to Peritoneal Mesothelioma:



Diseases related to Peritoneal Mesothelioma

Symptoms & Phenotypes for Peritoneal Mesothelioma

UMLS symptoms related to Peritoneal Mesothelioma:


abdominal pain

MGI Mouse Phenotypes related to Peritoneal Mesothelioma:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 CDKN2A EGFR ESR1 FGF2 NF2 THBD
2 cardiovascular system MP:0005385 10.09 CDKN2A EGFR ESR1 FGF2 THBD VEGFA
3 embryo MP:0005380 10.08 WT1 CDKN2A EGFR ESR1 NF2 THBD
4 hematopoietic system MP:0005397 10.05 CDKN2A EGFR ESR1 FGF2 THBD VEGFA
5 immune system MP:0005387 10.02 CDKN2A EGFR ESR1 NF2 THBD VEGFA
6 mortality/aging MP:0010768 10.01 CDKN2A EGFR ESR1 FGF2 NF2 THBD
7 endocrine/exocrine gland MP:0005379 10 CDKN2A EGFR ESR1 NF2 VEGFA WT1
8 liver/biliary system MP:0005370 9.98 CDKN2A EGFR ESR1 NF2 THBD VEGFA
9 integument MP:0010771 9.93 CDKN2A EGFR ESR1 NF2 THBD VEGFA
10 neoplasm MP:0002006 9.87 WT1 CDKN2A EGFR ESR1 FGF2 NF2
11 muscle MP:0005369 9.85 CDKN2A EGFR ESR1 FGF2 VEGFA WT1
12 reproductive system MP:0005389 9.76 CDKN2A EGFR ESR1 FGF2 NF2 THBD
13 renal/urinary system MP:0005367 9.73 EGFR ESR1 NF2 THBD VEGFA WT1
14 respiratory system MP:0005388 9.5 CDKN2A EGFR ESR1 NF2 THBD VEGFA
15 skeleton MP:0005390 9.1 CDKN2A EGFR ESR1 FGF2 NF2 VEGFA

Drugs & Therapeutics for Peritoneal Mesothelioma

Drugs for Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Doxil Approved June 1999 Phase 3,Phase 2 31703
3 Ranpirnase Investigational Phase 3 196488-72-9
4 Anti-Bacterial Agents Phase 3,Phase 2
5 Antibiotics, Antitubercular Phase 3,Phase 2
6 Topoisomerase Inhibitors Phase 3,Phase 2
7
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
8
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
9
Gemcitabine Approved Phase 2 95058-81-4 60750
10
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
11
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
12
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
13
Fluorouracil Approved Phase 2 51-21-8 3385
14
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
15
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
16
Pancrelipase Approved Phase 2 53608-75-6
17
Promethazine Approved Phase 2 60-87-7 4927
18
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
19
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
20
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
21
Pembrolizumab Approved Phase 2 1374853-91-4
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3
23
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
24
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
25
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
28
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
29 Anti-Infective Agents Phase 2,Phase 1
30 Antimetabolites Phase 2
31 Antimetabolites, Antineoplastic Phase 2
32 Antiviral Agents Phase 2,Phase 1
33 Immunosuppressive Agents Phase 2,Phase 1
34 Alkylating Agents Phase 2,Phase 1
35 Interferon-gamma Phase 2
36 interferons Phase 2,Phase 1
37 Mitomycins Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
39
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
40 Protein Kinase Inhibitors Phase 2,Phase 1
41 Folic Acid Antagonists Phase 2,Phase 1
42 Vitamin B Complex Phase 2,Phase 1
43 Albumin-Bound Paclitaxel Phase 2,Phase 1
44 Antimitotic Agents Phase 2,Phase 1
45 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
46 Cortisol succinate Phase 2
47 Hydrocortisone 17-butyrate 21-propionate Phase 2
48 Hydrocortisone acetate Phase 2
49 pancreatin Phase 2
50 Pharmaceutical Solutions Phase 2

Interventional clinical trials:

(show all 39)

id Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
3 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
4 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
5 Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis Unknown status NCT00454519 Phase 2
6 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed NCT01592383 Phase 2 erlotinib hydrochloride
7 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
8 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
9 Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
10 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Recruiting NCT02588131 Phase 2 tremelimumab plus MEDI4736
11 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Recruiting NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
12 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Recruiting NCT02588781 Phase 2 Pemetrexed
13 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
14 Pembrolizumab in Treating Patients With Malignant Mesothelioma Recruiting NCT02399371 Phase 2
15 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
16 Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Recruiting NCT02349958 Phase 2
17 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2 Tremelimumab;Placebo
18 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Active, not recruiting NCT01160458 Phase 2 IMC-A12
19 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Active, not recruiting NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
20 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2
21 Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment Not yet recruiting NCT01627795 Phase 1, Phase 2 Oshadi D and Oshadi R
22 A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma Withdrawn NCT01353482 Phase 1, Phase 2 Cisplatin;Pemetrexed;Vorinostat;Placebo
23 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma Completed NCT02141347 Phase 1 Tremelimumab;MEDI4736
24 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Completed NCT00402766 Phase 1 Cisplatin;Imatinib Mesylate;Pemetrexed;Dexamethasone
25 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Completed NCT00436657 Phase 1 CHPP of Cisplatin
26 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma Completed NCT00398138 Phase 1
27 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02029690 Phase 1 ADI-PEG 20
28 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Recruiting NCT02798536 Phase 1 LMB-100;nab-paclitaxel
29 CAR T Cells in Mesothelin Expressing Cancers Recruiting NCT03054298 Phase 1
30 Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Active, not recruiting NCT01439152 Phase 1 BAY94-9343;BAY94-9343 (Expansion);BAY94-9343 (1.8 mg/kg);BAY94-9343 (2.2 mg/kg)
31 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
32 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
33 Thrombin Generation and Platelet Activation in CRS/HIPEC Completed NCT03034850
34 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Sur Recruiting NCT01416714
35 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
36 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
37 An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting NCT02754115
38 Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies Recruiting NCT02073500
39 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169

Search NIH Clinical Center for Peritoneal Mesothelioma

Genetic Tests for Peritoneal Mesothelioma

Anatomical Context for Peritoneal Mesothelioma

MalaCards organs/tissues related to Peritoneal Mesothelioma:

39
Lung, Colon, Pancreas, T Cells, Myeloid, Lymph Node, Ovary

Publications for Peritoneal Mesothelioma

Articles related to Peritoneal Mesothelioma:

(show top 50) (show all 375)
id Title Authors Year
1
Current management strategies for peritoneal mesothelioma. ( 28664790 )
2017
2
Presentation of a malignant peritoneal mesothelioma in the forma of rough hepatic calcifications. ( 28480727 )
2017
3
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. ( 28189456 )
2017
4
Unusual presentation of a late-onset recurrence of malignant peritoneal mesothelioma. ( 28264807 )
2017
5
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. ( 28594258 )
2017
6
Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma. ( 28215643 )
2017
7
Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. ( 28540826 )
2017
8
Diffuse peritoneal mesothelioma: A case series of 62 patients including paraoccupational exposures to chrysotile asbestos. ( 28940402 )
2017
9
Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array. ( 28829357 )
2017
10
Multicystic peritoneal mesothelioma: A short review. ( 28528021 )
2017
11
Malignant peritoneal mesothelioma: a review. ( 28706904 )
2017
12
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. ( 28849389 )
2017
13
A case of malignant peritoneal mesothelioma suggesting the utility of combining double-contrast radiography and endoscopy with computed tomography for diagnosis. ( 28646342 )
2017
14
Benign Multicystic Peritoneal Mesothelioma: A Rare Condition in an Uncommon Gender. ( 28607791 )
2017
15
The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases. ( 28123552 )
2017
16
Malignant peritoneal mesothelioma - a rare cause of laparotomy. ( 28702106 )
2017
17
Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. ( 28324285 )
2017
18
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. ( 28761723 )
2017
19
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. ( 28910456 )
2017
20
miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. ( 28716051 )
2017
21
A Rare Case of Biphasic Malignant Peritoneal Mesothelioma with Refractory Ascites. ( 28381756 )
2017
22
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation. ( 28469343 )
2017
23
Reproducibility for histologic parameters in peritoneal mesothelioma. ( 28712777 )
2017
24
Rapamycin Treatment for Benign Multicystic Peritoneal Mesothelioma: A Rare Disease with a Difficult Management. ( 28579603 )
2017
25
Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. ( 28830230 )
2017
26
Remote Recurrence of Benign Multicystic Peritoneal Mesothelioma. ( 28733062 )
2017
27
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. ( 28877056 )
2017
28
Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma. ( 27428868 )
2016
29
Benign Cystic Peritoneal Mesothelioma Revealed by Small Bowel Obstruction. ( 27066288 )
2016
30
CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis. ( 26645426 )
2016
31
Malignant peritoneal mesothelioma and Crohn disease. ( 27484913 )
2016
32
A Case of Encapsulating Peritoneal Sclerosis Complicated by Malignant Peritoneal Mesothelioma. ( 27628605 )
2016
33
The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. ( 27858567 )
2016
34
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. ( 27472649 )
2016
35
Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma. ( 27127140 )
2016
36
Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization-array. ( 27184482 )
2016
37
Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma. ( 27612411 )
2016
38
Renal cell carcinoma and malignant peritoneal mesothelioma after occupational asbestos exposure: case report. ( 27240221 )
2016
39
Diffuse malignant peritoneal mesothelioma presenting with psammomatous calcification on a cervical smear: A case report. ( 27773157 )
2016
40
Diffuse malignant biphasic peritoneal mesothelioma with cystic areas. ( 27320084 )
2016
41
Diagnosis and management of patients with malignant peritoneal mesothelioma. ( 26941986 )
2016
42
CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. ( 26810896 )
2016
43
Pathology in Practice. Peritoneal Mesothelioma With Metastasis to Adrenal glands, Heart, and Lungs. ( 26684092 )
2016
44
Metachronous Uterine Endometrioid Adenocarcinoma and Peritoneal Mesothelioma in Lynch Syndrome: A Case Report. ( 27903930 )
2016
45
Benign Multicystic Peritoneal Mesothelioma: AIRP Best Cases in Radiologic-Pathologic Correlation. ( 26963453 )
2016
46
Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma. ( 27343465 )
2016
47
A Case of Abdominal Discomfort Caused by Benign Multicystic Peritoneal Mesothelioma. ( 27264391 )
2016
48
Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy. ( 27858561 )
2016
49
Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. ( 27705913 )
2016
50
Imaging appearance of benign multicystic peritoneal mesothelioma: a case report and review of the literature. ( 27984828 )
2016

Variations for Peritoneal Mesothelioma

Expression for Peritoneal Mesothelioma

Search GEO for disease gene expression data for Peritoneal Mesothelioma.

Pathways for Peritoneal Mesothelioma

Pathways related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1 12.35 CDKN2A EGFR FGF2 VEGFA
2
Show member pathways
12.23 CDKN2A EGFR ESR1 FGF2 VEGFA
3
Show member pathways
11.97 EGFR FGF2 VEGFA
4 11.87 EGFR ESR1 VEGFA
5 11.8 FGF2 VEGFA WT1
6 11.67 FGF2 MUC1 VEGFA
7 11.63 CDKN2A EGFR NF2
8 11.56 EGFR ESR1 FGF2 VEGFA
9
Show member pathways
11.51 EGFR ESR1 VEGFA
10 11.36 CDKN2A EGFR VEGFA
11
Show member pathways
11.28 EGFR ESR1 VEGFA
12 11.15 EGFR ESR1 WT1
13 10.96 FGF2 VEGFA
14 10.9 FGF2 VEGFA
15 10.48 EGFR ESR1 VEGFA

GO Terms for Peritoneal Mesothelioma

Biological processes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of transcription from RNA polymerase II promoter GO:0006357 9.78 EGFR ESR1 VEGFA WT1
2 positive regulation of transcription, DNA-templated GO:0045893 9.55 CDKN2A EGFR ESR1 FGF2 WT1
3 positive regulation of blood vessel endothelial cell migration GO:0043536 9.46 FGF2 VEGFA
4 negative regulation of cell-matrix adhesion GO:0001953 9.43 CDKN2A NF2
5 epithelial cell differentiation GO:0030855 9.43 MUC1 VEGFA WT1
6 mammary gland alveolus development GO:0060749 9.4 ESR1 VEGFA
7 cell migration involved in sprouting angiogenesis GO:0002042 9.37 FGF2 VEGFA
8 positive regulation of phospholipase C activity GO:0010863 9.32 ESR1 FGF2
9 positive regulation of MAP kinase activity GO:0043406 9.13 EGFR FGF2 VEGFA
10 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.1 CDKN2A EGFR ESR1 FGF2 VEGFA WT1

Molecular functions related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.85 CDKN2A EGFR ESR1 FGF2 KRT20 MUC1
2 chemoattractant activity GO:0042056 8.96 FGF2 VEGFA
3 nitric-oxide synthase regulator activity GO:0030235 8.62 EGFR ESR1

Sources for Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....